HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen

被引：27

作者：

Marcelin, Anne-Genevieve ^{[1
]}

Jarrousse, Bernard

Derache, Anne

Ba, Madina

Dakouo, Marie-lea

Doumbia, Alioune

Haidara, Lbrahima

Maiga, Almoustapha

Carcelain, Guislaine

Peytavin, Gilles

Katlama, Christine

Calvez, Vincent

机构：

[1] Hop La Pitie Salpetriere, Paris, France

[2] SOLTHIS Segou, Solidarite Therapeut & Initiat SIDA, Paris, France

[3] ONG Wale, Segou, Mali

[4] ONG APROFEM, Segou, Mali

[5] Hop Bichat Claude Bernard, F-75877 Paris 18, France

来源：

AIDS | 2007年 / 21卷 / 17期

关键词：

D O I：

10.1097/QAD.0b013e328235a527

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Early failures to stavudine/lamivudine/nevirapine used as a generic fixed-dose combination in Mali showed resistance mutations in 50% of cases (mostly M184V and Y181C). No thymidine analogue mutations were seen, suggesting that most nucleoside reverse transcriptase inhibitors could be used in a second-line regimen. This highlights the importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-poor countries to detect early virological failure in order to preserve future therapeutic options.

引用

页码：2341 / 2343

页数：3

共 11 条

[1]

Bourgeois A, 2005, ANTIVIR THER, V10, P335

[2] Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort [J].

Calmy, Alexandra ;

Pinoges, Lorextu ;

Szumilin, Elisabeth ;

Zachariah, Rony ;

Ford, Nathan ;

Ferradini, Laurent .

AIDS, 2006, 20 (08) :1163-1169

[3] Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen [J].

Delaugerre, C ;

Rohban, R ;

Simon, A ;

Mouroux, M ;

Tricot, C ;

Agher, R ;

Huraux, JM ;

Katlama, C ;

Calvez, V .

JOURNAL OF MEDICAL VIROLOGY, 2001, 65 (03) :445-448

[4] Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance [J].

Descamps, D ;

Delaugerre, C ;

Masquelier, B ;

Ruffault, A ;

Marcelin, AG ;

Izopet, J ;

Chaix, ML ;

Calvez, V ;

Brun-Vézinet, F ;

Costagliola, D .

JOURNAL OF MEDICAL VIROLOGY, 2006, 78 (02) :153-160

[5] Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine - HIVNET 012 [J].

Eshleman, SH ;

Guay, LA ;

Wang, J ;

Mwatha, A ;

Brown, ER ;

Musoke, P ;

Mmiro, F ;

Jackson, JB .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (01) :24-29

[6]

Johnson Victoria A, 2006, Top HIV Med, V14, P125

[7] Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon:: open-label multicentre trial [J].

Laurent, C ;

Kouanfack, C ;

Koulla-Shiro, S ;

Nkoué, N ;

Bourgeois, A ;

Calmy, A ;

Lactuock, B ;

Nzeusseu, V ;

Mougnutou, R ;

Peytavin, G ;

Liégeois, F ;

Nerrienet, E ;

Tardy, M ;

Peeters, M ;

Andrieux-Meyer, I ;

Zekeng, L ;

Kazatchkine, M ;

Mpoudi-Ngolé, E ;

Delaporte, E .

LANCET, 2004, 364 (9428) :29-34

[8] HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen [J].

Martinez, V ;

Marcelin, AG ;

Morini, JP ;

Deleuze, J ;

Krivine, A ;

Gorin, I ;

Yerly, S ;

Perrin, L ;

Peytavin, G ;

Calvez, V ;

Dupin, N .

AIDS, 2005, 19 (10) :1065-1069

[9]

Mouroux M, 2001, ANTIVIR THER, V6, P179

[10] NEVIRAPINE RESISTANCE MUTATIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SELECTED DURING THERAPY [J].

RICHMAN, DD ;

HAVLIR, D ;

CORBEIL, J ;

LOONEY, D ;

IGNACIO, C ;

SPECTOR, SA ;

SULLIVAN, J ;

CHEESEMAN, S ;

BARRINGER, K ;

PAULETTI, D ;

SHIH, CK ;

MYERS, M ;

GRIFFIN, J .

JOURNAL OF VIROLOGY, 1994, 68 (03) :1660-1666

← 1 2 →